Appeal 2007-2523
Application 10/370,749
two constant domains” (id.) and is “involved in non-antigen binding
functions” (id. at 1). For example, it “binds Fc receptors, which may trigger
. . . antibody dependent cellular cytotoxicity (ADCC)” (id. at 2).
The Specification refers to “compositions comprising a variant . . . of
a parent polypeptide having at least a portion of an Fc region, wherein the
variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in
the presence of effector cells more effectively than the parent polypeptide
and comprises at least one amino acid modification at position 280 in the Fc
region” (id.). Specifically, the Specification describes an “amino acid
modification at position 280 in the Fc region selected from D280H, D280Q,
and D280Y”; i.e., substitution of histidine (H), glutamine (Q), or tyrosine
(Y) for the naturally occurring aspartic acid (D) at position 280 (id. at 3).
The Specification also describes a variant comprising an antibody or
immunoadhesin (id. at 4).
DISCUSSION
1. CLAIMS
Claims 1-3, 5-8, and 10 are on appeal. Claims 11-20 are also pending
but have been withdrawn from consideration by the Examiner. We will
focus on claim 1, the broadest claim on appeal, which reads as follows:
1. A composition comprising a variant of a parent polypeptide having at
least a portion of an Fc region, wherein said variant mediates antibody-
dependent cell-mediated cytotoxicity (ADCC) in the presence of effector
cells more effectively than said parent polypeptide, wherein said variant
comprises a histidine, glutamine or tyrosine amino acid at position 280 in the
Fc region, and wherein said parent polypeptide is an antibody or
immunoadhesin.
2
Page: Previous 1 2 3 4 5 6 7 Next
Last modified: September 9, 2013